Summary of Study ST003358

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002085. The data can be accessed directly via it's Project DOI: 10.21228/M83R6P This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003358
Study TitleSecretion of sphingomyelin from Huh7 cells treated with various fatty acids including of oleate-d9 and elaidate-d17.
Study SummaryWe analyzed sphingomyelin (SM) in fresh and spent media from Huh7 cells treated with BSA-EtOH, BSA-palmitate, BSA-stearate, BSA-oleate-d9 or BSA-elaidate-d17. We aimed to determine the secretory flux of SM induced by various fatty acid treatments.
Institute
Salk Institute for Biological Studies
Last NameGengatharan
First NameJivani
Address10010 N Torrey Pines Rd, La Jolla, CA, 92037, USA
Emailjivani14@gmail.com
Phone(858) 453-4100
Submit Date2024-07-30
Raw Data AvailableYes
Raw Data File Type(s)d
Analysis Type DetailLC-MS
Release Date2024-08-09
Release Version1
Jivani Gengatharan Jivani Gengatharan
https://dx.doi.org/10.21228/M83R6P
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR002085
Project DOI:doi: 10.21228/M83R6P
Project Title:Altered sphingolipid biosynthetic flux and lipoprotein trafficking contribute to trans fat-induced atherosclerosis
Project Summary:The goal of the project is to determine the role of sphingolipid metabolism in atherosclerosis induced by dietary trans fat. We analyzed lipid metabolites in Huh7 cells following various fatty acid treatments, with specific focus on cis and trans unsaturated fatty acids. Additionally, we analyzed lipid metabolites in plasma and liver of Ldlr-/- mice fed high-fat diets enriched in cis or trans fatty acids in the presence or absence of myriocin, a pharmacological inhibitor of Serine palmitoyltransferase (SPT), the initial rate-limiting enzyme of sphingolipid biosynthesis.
Institute:Salk Institute for Biological Studies
Last Name:Gengatharan
First Name:Jivani
Address:10010 N Torrey Pines Rd, La Jolla, CA, 92037, USA
Email:jivani14@gmail.com
Phone:(858) 453-4100

Subject:

Subject ID:SU003479
Subject Type:Cultured cells
Subject Species:Homo sapiens
Taxonomy ID:9606
Cell Strain Details:Huh7

Factors:

Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sample source Condition
SA365818Huh7freshmedia_C8SL2_d17elaidic2Huh7 media BSA-elaidate-d17 fresh media
SA365819Huh7freshmedia_C8SL2_d17elaidic1Huh7 media BSA-elaidate-d17 fresh media
SA365820Huh7spentmedia_C8SL2_d17elaidic3Huh7 media BSA-elaidate-d17 spent media
SA365821Huh7spentmedia_C8SL2_d17elaidic2Huh7 media BSA-elaidate-d17 spent media
SA365822Huh7spentmedia_C8SL2_d17elaidic1Huh7 media BSA-elaidate-d17 spent media
SA365814Huh7freshmedia_C8SL2_EtOH1Huh7 media BSA-EtOH fresh media
SA365815Huh7spentmedia_C8SL2_EtOH2Huh7 media BSA-EtOH spent media
SA365816Huh7spentmedia_C8SL2_EtOH1Huh7 media BSA-EtOH spent media
SA365817Huh7spentmedia_C8SL2_EtOH3Huh7 media BSA-EtOH spent media
SA365823Huh7freshmedia_C8SL2_d9oleic1Huh7 media BSA-oleate-d9 fresh media
SA365824Huh7freshmedia_C8SL2_d9oleic2Huh7 media BSA-oleate-d9 fresh media
SA365825Huh7spentmedia_C8SL2_d9oleic1Huh7 media BSA-oleate-d9 spent media
SA365826Huh7spentmedia_C8SL2_d9oleic3Huh7 media BSA-oleate-d9 spent media
SA365827Huh7spentmedia_C8SL2_d9oleic2Huh7 media BSA-oleate-d9 spent media
SA365828Huh7freshmedia_C8SL2_palm2Huh7 media BSA-palmitate fresh media
SA365829Huh7freshmedia_C8SL2_palm1Huh7 media BSA-palmitate fresh media
SA365830Huh7spentmedia_C8SL2_palm2Huh7 media BSA-palmitate spent media
SA365831Huh7spentmedia_C8SL2_palm1Huh7 media BSA-palmitate spent media
SA365832Huh7spentmedia_C8SL2_palm3Huh7 media BSA-palmitate spent media
SA365833Huh7freshmedia_C8SL2_stear1Huh7 media BSA-stearate fresh media
SA365834Huh7freshmedia_C8SL2_stear2Huh7 media BSA-stearate fresh media
SA365835Huh7spentmedia_C8SL2_stear3Huh7 media BSA-stearate spent media
SA365836Huh7spentmedia_C8SL2_stear2Huh7 media BSA-stearate spent media
SA365837Huh7spentmedia_C8SL2_stear1Huh7 media BSA-stearate spent media
Showing results 1 to 24 of 24

Collection:

Collection ID:CO003472
Collection Summary:0.75 ml of fresh media or 1.5 ml of spent media was evaporated under vacuum at 4°C and resuspended into 0.1 mL of H2O. Concentrated media was spiked with the following internal standards: 20 pmol sphinganine-d7 (Avanti Polar Lipids, Cat# 860658), deoxysphinganine-d3 (Avanti Polar Lipids, Cat# 860474), 100 pmol d18:0-d7/13:0 dihydroceramide (Avanti Polar Lipids, Cat# 330726), 200 pmol d18:1-d7/15:0 ceramide (Avanti Polar Lipids, Cat# 860681), 100 pmol d18:1-d7/15:0 glucosylceramide (Avanti Polar Lipids, Cat# 330729), 100 pmol d18:1-d7/15:0 lactosylceramide (Avanti Polar Lipids, Cat# 330727), 200 pmol sphingosine-d7 (Avanti Polar Lipids, Cat# 860657).
Sample Type:Cultured cells

Treatment:

Treatment ID:TR003488
Treatment Summary:Huh7 cells were treated with 1) 100 µM BSA-EtOH, 2) 100 µM BSA-palmitate, 3) 100 µM BSA-stearate , 4) 100 µM BSA-oleate-d9 or 5) 100 µM BSA-elaidate-d17 for 48 hours in delipidated media.

Sample Preparation:

Sampleprep ID:SP003486
Sampleprep Summary:0.75 ml of fresh media or 1.5 ml of spent media was evaporated under vacuum at 4°C and resuspended into 0.1 mL of H2O. Concentrated media was spiked with the following internal standards: 20 pmol sphinganine-d7 (Avanti Polar Lipids, Cat# 860658), deoxysphinganine-d3 (Avanti Polar Lipids, Cat# 860474), 100 pmol d18:0-d7/13:0 dihydroceramide (Avanti Polar Lipids, Cat# 330726), 200 pmol d18:1-d7/15:0 ceramide (Avanti Polar Lipids, Cat# 860681), 100 pmol d18:1-d7/15:0 glucosylceramide (Avanti Polar Lipids, Cat# 330729), 100 pmol d18:1-d7/15:0 lactosylceramide (Avanti Polar Lipids, Cat# 330727), 200 pmol sphingosine-d7 (Avanti Polar Lipids, Cat# 860657). 0.5 mL methanol, 0.5 mL H2O, and 1 mL chloroform were added directly. Samples were vortexed for 5 min and centrifuged for 5 min at 4 ˚C at 15,000g. The organic phase was collected and 2 μL of formic acid was added to the remaining polar phase which was re-extracted with 1 mL of chloroform. Combined organic phases were dried under nitrogen. After dried extracts for media were resuspended in 60 µl Buffer B, 5 µL of sample was injected.

Combined analysis:

Analysis ID AN005500
Analysis type MS
Chromatography type Reversed phase
Chromatography system Agilent 1260 Infinity II
Column Peeke Scientific Spectra C8SR (150 x 3.0 mm, 3μm)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name Agilent 6460 QQQ
Ion Mode POSITIVE
Units Peak area

Chromatography:

Chromatography ID:CH004182
Instrument Name:Agilent 1260 Infinity II
Column Name:Peeke Scientific Spectra C8SR (150 x 3.0 mm, 3μm)
Column Temperature:40˚C
Flow Gradient:0 min, 82% B; 3 min, 82% B; 4 min, 90% B; 18 min, 99% B; 25 min, 99% B; 27 min, 82% B; 30 min, 82% B
Flow Rate:0.5 mL/min
Solvent A:100% water; 0.2% formic acid; 2 mM ammonium formate
Solvent B:100% methanol; 0.2% formic acid; 1 mM ammonium formate
Chromatography Type:Reversed phase

MS:

MS ID:MS005226
Analysis ID:AN005500
Instrument Name:Agilent 6460 QQQ
Instrument Type:Triple quadrupole
MS Type:ESI
MS Comments:Sphingolipid species were analyzed by multiple reaction monitoring of the transition from precursor to product ions at associated optimized collision energies, and fragmentor voltages using Agilent Masshunter. The m/z values of the precursor and product ions are provided in the metabolite metadata section.
Ion Mode:POSITIVE
  logo